Possibilities of atorvastatin in complex management of extensive psoriasis in patients with arterial hypertension

Kardiologiya

Volumn 50, Issue 3, 2010, Pages 37-46

  Vasyuk, Yu A ^a   Perlamutrov, Yu N ^a   Shkolnik, M N ^a   Shkolnik, E L ^a  

^a A I EVDOKIMOV MOSCOW STATE UNIVERSITY OF MEDICINE AND DENTISTRY   (Russian Federation)

Author keywords

Atorvastatin; Hypertension; Inflammation; Psoriasis

Indexed keywords

ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FOLLOW UP; HOSPITALIZATION; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN; TREATMENT OUTCOME;

BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; MIDDLE AGED; PSORIASIS; PYRROLES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SKIN; TREATMENT OUTCOME;

EID: 77954922252     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Schon M.P., Boehncke W.H. Psoriasis. N Engl J Med 2005;352:1899-1912. (Pubitemid 40627816)
2. Krueger J.G., Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005;64:30-36.
3. Veale D.J., Ritchlin C., FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005;64:26-29.
4. Wojas-Pelc A., Rajzer L., Rajzer U. Psoriasis and cardio-vascular disorders. Przegl Lek 2002:59:844-847.
5. Grzybowski G. et al. Evaluation of glucose, insulin, C-peptide uric acid serum levels in patients with psoriasis. Pol Merkur Lekarski 2001;11:495-498.
6. Henseier T., Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-986.
7. Corsini A., Jacobson T.A., Ballantyne C.M. Fluvastatin: clinical and safety profile. Drugs 2004;64:1305-1323. (Pubitemid 38916344)
8. Downs J.R. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-1622. (Pubitemid 28248586)
9. Nissen S.E. et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-1565.
10. Seed M., Weir M.R. Double-masked comparison of the quality of life of hypercholesterolemic men treated with simvastatin or pravastatin. International Quality of Life Multicenter Group. Clin Ther 1999;21:1758-1770. (Pubitemid 29523370)
11. Shepherd J. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. PROspective Study of Pravastatin in the Elderly at Risk. Lancet 2002;360:1623-1630. (Pubitemid 35379733)
12. Magen E., Viskoper R., Mishal J. et al. Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C., for blood pressure control. Isr Med Assoc J 2004;6:742-746. (Pubitemid 39646687)
13. Terzoli L., Mircoli L., Raco R., Ferrari A.M. Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors. J Cardiovasc Pharmacol 2005;46:310-315. (Pubitemid 41262833)
14. Paragh G, Mark L., Katona E. The non-lipid effects of statins Orv Hetil 2004;145:1903-1910.
15. Wemer N., Nickenig G, Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors Basic Res Cardiol 2002;97:105-116. (Pubitemid 34223500)
16. Danesh F.R., Anel R.L., Zeng L., Lomasney J., et al. Immunomodulatory effects of HMG-CoA reductase inhibitors. Arch Immunol Ther Exp (Warsz) 2003;51:139-148. (Pubitemid 36828176)
17. Weitz-Schmidt G. et al. Improved lymphocyte function-associated antigen-1 (LFA-1) inhibition by statin derivatives. J Biol Chemi 2004;279:46764-46771.
18. Methe H. et al. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol 2005;25:1439-1445. (Pubitemid 40923365)
19. Zubelewicz-Szkodzinska B., Szkodzinski J., Romanowski W. et al. Simvastatin decreases concentration of interleukin-2 in hypercholesterolemic patients after treatment for 12 weeks. J Biol Regul Homeost Agents 2004;18:295-301. (Pubitemid 40723668)
20. Bone H. G. et al. Effects of Atorvastatin on Bone in Postmenopausal Women with Dyslipidemia: A Double-Blind, Placebo-Controlled, Dose-Ranging Trial. J Clin Endocrinol Metab 2006;92:4671-4677.
21. Williams B., Lacy P.S., Cruickshank J.K. et al. CAFE and ASCOT Investigators. Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study. Circulation 2009;119:53-61.
22. Shirinsky I.V., Shirinsky V.S. Efficacy of simvastatin in plaque psoriasis: A pilot study. J Am Acad Dermatol 2007;57:529-531. (Pubitemid 47239149)
23. Hilgendorff A., Muth H, Parviz B. et al. Statins differ in their ability to block NF-cappa-B activation in human blood monocytes. Int J Clin Pharmacol Ther 2003;41:397-401. (Pubitemid 37138482)
24. Kumagai K., Nakashima H., Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004;62:105-111. (Pubitemid 38326816)
25. Ozaydin M. et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006;97:1490-1493.
26. Siu C. et al. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 2003;92:1343-1345. (Pubitemid 37431149)
27. Nishikawa H, Miura S., Zhang B. et al. Statins induce the regression of left ventricular mass in patients with angina. Circ J 2004;68:121-125. (Pubitemid 38197247)
28. Su S.F., Hsiao C.L., Chu C. W. et al. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. Am J Cardiol 2000;86:514-518.
29. Bauersachs J., Stork S., Kung M. et al. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study. Eur J Clin Invest 2007;37:852-859. (Pubitemid 350029212)
30. Simko F. Statins: a perspective for left ventricular hypertrophy treatment. Eur J Clin Invest 2007;37:681-691. (Pubitemid 47256168)
31. Strober B., Teller C., Yamauchi P. et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008;159:322-330. (Pubitemid 352009830)
32. 2-macroglobulin plasma activity in medium-severe and severe psoriasis JEADV2004;18:180-183. (Pubitemid 38379896)
33. Borska L. et al. Immunologic changes in TNF-alpha, sE-selectin, sP-selectin, sICAM-1, and IL-8 in pediatrie patients treated for psoriasis with the goeckerman regimen. Pediatr Dermatol 2007;24.607-612. (Pubitemid 350173678)
34. Numerof R.P., Asadullah K. Cytokine and anti-cytokine therapies for psoriasis and atopic dermatitis. Biodrugs 2006;20:93-103.
35. Jacob S.E., Nassiri M., Kerdel F.A. et al. Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm 2003;12:309-313. (Pubitemid 37392904)
36. Szegedi A., Aleksza M., Gonda A, et al. Elevated rate of Thelperl (Th1) lymphocytes and serum IFN-γ levels in psoriatic patients. Immunol Lett 2003;86:277-280. (Pubitemid 36428688)
37. Borska L. et al. Serum levels of the pro-inflammatory cytokine interleukin-12 and the anti-inflammatory cytokine interleukin-10 in patients with psoriasis treated by the Goeckerman regimen. Intern J Dermatol 2008;47:800-805.
38. Roussaki-Schulze A.V., Kouskoukis C., Petinaki E. et al. Evaluation of cytokine serum levels in patients with plaquetype psoriasis. Int J Clin Pharmacol Res 2005;25:169-173. (Pubitemid 41810112)
39. Cordiali-Fei P. et al. Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-α. J Autoimmune Dis 2006;3:5.
40. Ogilve A.L., Lüftl M., Antoni C. et al. Leukocyte infiltration and mRNA expression of 1L-20, IL-8 and TNF-R P60 in psoriatic skin is driven by TNF-alpha. Int J Immunopathol Pharmacol 2006;19:271-278. (Pubitemid 44181950)
41. Guttman-Yassky E., Vugmeyster Y, Lowes M.A. et al. Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness. J Invest Dermatol 2008; 128:1182-1191. (Pubitemid 351543222)
42. Lowes U.A. Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a) PNAS 2005;102:19057-19062.